Working… Menu
Trial record 1 of 1 for:    NCT03546361
Previous Study | Return to List | Next Study

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03546361
Recruitment Status : Recruiting
First Posted : June 6, 2018
Last Update Posted : February 25, 2021
California Institute for Regenerative Medicine (CIRM)
Merck Sharp & Dohme Corp.
Lungevity Foundation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2023